Regeneron Drug’s Benefit May Not Outweigh Risk, FDA Says

Regeneron Pharmaceuticals Inc.’s Arcalyst may not offer enough of a benefit in preventing gout flares to be worth the risk of developing cancer, U.S. regulators said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.